http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2875535-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_431309bc8dab94a0ee0e2aa5aeacd48d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70546 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6876 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1f9538c69107d618678f4a12eadbefc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e98f4dc4de8824ac7a00bbd148eb009 |
| publicationDate | 2021-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2875535-T3 |
| titleOfInvention | Biomarkers for use in Integrin Therapy Applications |
| abstract | A method of predicting whether a human subject having an αvβ6-mediated disorder will respond to treatment with an αvβ6 integrin inhibitor, the method comprising: a) providing a biological sample that has been obtained from the human subject after administration of the integrin inhibitor αvβ6; and b) measuring the expression level of one or more genes or proteins selected from the group consisting of arachidonate 5-lipoxygenase 5 (ALOX5), fibronectin (FN1), oxidized low-density lipoprotein receptor 1 (OLR1), inhibitor of activator of plasminogen 1 (PAI-1 or SERPINE1), transglutaminase 2 (TGM2), and trigger receptor expressed in myeloid cells 1 (TREM1) in the biological sample, in which a decrease in the expression level of one or more genes or proteins relative to a control expression level predicts that the human subject will respond, or is more likely to respond, to treatment with the αvβ6 integrin inhibitor, wherein the αvβ6-mediated disorder is selected from the group consisting of pulmonary fibrosis, pulmonary fibrosis idiopathic, radiation-induced fibrosis, bleomycin-induced fibrosis, asbestos-induced fibrosis, lung cancer and acute lung injury, scleroderma, in which αvβ6 integrin inhibitor is an an αvβ6 anti-integrin antibody, and wherein the biological sample is bronchoalveolar lavage fluid. |
| priorityDate | 2012-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 100.